Jump to content

Leaderboard


Popular Content

Showing content with the highest reputation since 01/07/2019 in all areas

  1. 2 points
    New CN policy looks to be targeting 2019 installations greater than 2018. Seems to set targets of around 45GW. http://guangfu.bjx.com.cn/news/20190219/963630.shtml According to the most conservative estimate, the installed capacity of photovoltaics will reach more than 45 million kilowatts in 2019, which has exceeded 44.26 million kilowatts in 2018 http://guangfu.bjx.com.cn/news/20190219/963637.shtml In 2019, the subsidized rated installed capacity will be calculated according to the current expected 3 billion subsidy scale (excluding poverty alleviation). The subsidy intensity of the power subsidy is 0.075 yuan/kWh, and the subsidy scale is about 35.9 GW. (When the power subsidy intensity is 0.05 yuan/kWh, the subsidy scale is about 53.8GW), and then consider 5GW photovoltaic poverty alleviation and 5GW unsubsidized projects, and deduct about 1GW of household occupancy index after 2018 531, 2019 The installed capacity of photovoltaics in the year may reach 45GW, exceeding the installed capacity of 44.3GW in 2018.
  2. 2 points
    Awesome update from CSIQ. Beat on Q4.
  3. 2 points
    Hopefully not for a buyout at 18.60! Chuckle....
  4. 2 points
    The story of Canadian pipeline shrinking was heard loud and clear on this forum since Canadian plants were completed. The company is not only one pure developer still standing, but it is producing more and more business encompassing other arms of managing solar plants. It maintains healthy "sell and/or keep" strategy. There are many markets to go with solar plants. And those markets will expand. We have not seen any victims of the slowdowns with exception of few subs going bankrupt in China. There is plenty of space available. The manufacturing and the decisions made had worked thus far for the company. I am not sure why transformation, when required, would not be as well executed as it has been to date. Not sure why a successful organization would suddenly lose its footing. They are the most capable of a shift. FSLR has zero ability to shift, SPWR is dead, JKS is almost dead and will never be buried if it died, like Yingli, but CSIQ is somehow paralyzed and cannot make a move? I read those scenarios too many times. I argued against them as many, and I am surprised to see them again. Even Snake seems to be seeing Chinese taking FSLR to cleaners now. I do not have a skin in this game, but I think Canadian could surprise few folks here with its share price going forward. Cheers, I am back under the rock.
  5. 2 points
    While I understand (and, as a former [albeit small] JASO stockholder, share) the sentiment, I wouldn't put too much stock into this announcement (pun intended). First, since the guilty parties are all in China, I don't know if a US court has any jurisdiction over them. Second, Pomerantz are ambulance chasers. I've seen their name in dozens of headlines. A company will announce bad news one day, and the next half a dozen of these guys all announce lawsuits, including Pomerantz. I have never once heard of such a suit actually being successful. So this may be a Pyrrhic victory at best....
  6. 1 point
    Total renewable energy capacity passes that of coal in the U.S. FERC projections that Renewables will supply 1/3 of the capacity in a few years. https://solarindustrymag.com/renewables-finally-beat-coal-for-u-s-electrical-generating-capacity For the first time, U.S. electrical generating capacity by renewable energy sources – biomass, geothermal, hydropower, solar and wind – has surpassed that of coal, according to a SUN DAY Campaign analysis of new data from the Federal Energy Regulatory Commission (FERC).
  7. 1 point
    I know their bifacial panels are a small part of CSIQ's sales, but wouldn't they suddenly become the panel of choice in the U.S. if they avoid the 30% tariff and are more efficient? Not sure where they are on costs, but that 30% off seems like a great place to start. Looks like it's up a bit after hours since news posted.
  8. 1 point
    Vibes that the non-subsidy projects in China may take until 2022 or 2023 to be rolled out: Innovation and uncertainty mark SNEC 2019 https://www.pv-magazine.com/2019/06/07/innovation-and-uncertainty-mark-snec-2019/
  9. 1 point
    Biden to hand out 1.7 trillion to FSLR, me likes: https://www.cnn.com/2019/06/04/politics/joe-biden-2020-climate-plan/index.html
  10. 1 point
    I think you need to take with a grain of salt their stated costs. Typically costs are quarters end stated for internal production with current quarterly claimed margins. They have a large deferred revenue recognition with respect to their project builds and module acceptance periods of customers. This means that a large portion 30% or more could be from earlier builds as much as 6 months earlier when their costs were much higher than Q4 stated. For example it takes 1 to 2 months to freight ship. It could take another 1 to 2 months to get them installed. The contracts may also have acceptance clauses that require 6 months of running for baseline output. This suggests that a good portion of the quarterly recognized modules for revenues could be deffered from quarters back. Just look at Q1 where there revenue recognized modules were 1423MW and shipped is about 150MW more. As they mentioned they have over 900MW of EPC projects going on. That is the potential of 250MW a quarter in deferred sales until completed and acceptance. As they roll into more and more NTP this will be worse as will some of their major customer contracts like the recent 1.8GW contract. You also need to understand that not only is the deffered sales hitting their cost structure but it also props up the ASP. They are also being selective and selling to high margin markets and have built a direct sales team. These all lead to the higher ASP as well. The ASP was covered in a reply to Colin Rush.
  11. 1 point
    Looks like Aguascalientes is not a problem any more... http://investors.canadiansolar.com/news-releases/news-release-details/canadian-solar-completes-sale-aguascalientes-solar-project
  12. 1 point
    They should rename everything to losses instead of earnings. Losses release, losses con call, losses per share, etc. Complete crap. Used to be mad at the Chinese for keeping the dead alive (YGE) but turns out the westerners are not a bit better. Guess we're all human LOL.
  13. 1 point
    Well honeys the stock is up despite the heavy bashing earlier here. Let's just hope CSIQ behaves just as good after its ER. 🤪
  14. 1 point
    I've had my fair share of drama today with the kids so need no more. All these issues are peanuts compared to what's cooking at JKS's or CSIQ's. FSLR will make so much money over the next two years it s just obscene.
  15. 1 point
    I believe that article is incorrect in the period of the bookings. They PR'd http://ir.jinkosolar.com/news-releases/news-release-details/jinkosolar-secures-over-107-gw-orders-2019 "Jinko has announced they have contracted FOR 2019 10.7GW.." They did not state 10.7GW IN 2019 which would imply a 4 month bookings. This PR appears to be a cumulative statement for 2019 and not a new bookings in 2019. If that interpretation is correct, they have 3.3-4.3GW left to book for 2019. This would be bookings needed in the next 5 or 6 months. That is very attainable for them. This PR follows a notice of expanding 5GW of of Mono capacity pushing capacity to 11.5GW of Mono wafers. That is 500MW higher than previously guided in Q1. Phillip Shen asked some expansion questions the company indicated it needs some $400-$450M in Capex for the expansions this year. He also questioned them on the equity raising needed and where it comes from and it was clear they are looking at some equity raising. https://seekingalpha.com/article/4250602-jinkosolar-holding-co-ltd-jks-ceo-kangping-chen-q4-2018-results-earnings-call-transcript?part=single Based on the 2 back to back PR's which are basically an affirmation of their intended capacity expansions and progress for sales in 2019, the company is likely looking for positive press and stock so they can raise equity to pay for the capacity expansion.
  16. 1 point
    Congratulations! Nice to hear you've hit your goal.
  17. 1 point
    I think the real issue with FSLR is its risk concentration: Rely on US market dominated revenues Rely on temporary competition protection in US market Rely on temporary subsidies in US market Rely on competitive success of narrow field of CdTe manufacturing equipment development Rely on success of narrow field of rare Tellurium production Rely on continued wide market acceptance of toxic Cadmium So far there's been volatile reward for these risk bets. When one has failed another has delivered. It would seem prudent to spread bets.
  18. 1 point
    Approaching 50% return less than 4 months into the year. Nothing special in solar world, but this time my capital preservation strategy is better. After a long time of focus on asset allocation optimization and verification of Alpha and Beta return attribution I've recently focused more on return contribution analysis in order to verify that the allocation does not contain any poor contributors due to flawed strategy or tactic. I think that this continuous qualification of the strategy and tactic is key to long-term performance success. --- Goal Financial independence by 2030 Objective 15% annual return @ 25% volatility Strategy Rebalance optimal allocation Tactic Buy the dips and hold the rips Allocation Return
  19. 1 point
    Not sure, I'd guess 24-25 cts on a comparable basis.
  20. 1 point
    This is horrible for FSLR: "...Our module manufacturing cost in China, including purchased polysilicon, wafers and cells, decreased to $0.20 per watt in December 2018..."
  21. 1 point
    Looks like H2/2019 in China will be explosive: with about 15 GW PV installations per quarter... https://www.pv-tech.org/news/chinas-new-subsidy-programme-could-support-up-to-50gw-says-official
  22. 1 point
    Updated investor presentation out: http://investors.canadiansolar.com/static-files/48509dd8-8e15-4d99-90f8-c22fa89905f8 Anything interesting you guys? I noticed they've started playing with quasi-mono. But why?
  23. 1 point
    Hmmm, Q4 DQ had 61% production being mono. In Q1 they are forecasting 78% of their production will be mono. To me that sounds like the Multi ASP drop will not impact them significantly for now. As you can see from their transcript below they indicate that Mono would not drop much due to the production costs of most online. In fact they were suggesting due to ratios of mono vs multi poly and much better pricing on Mono and more production Q1 should be improved margins. As for the price tightening, when everyone refines and moves from junk poly to mono quality, then the Si price for Poly wafer production will rebound as the glut will be less. That price rebound for poly would create a narrowing in the price gap. That suggests that that while Mono may decline some, it will not necessarily decline much since the Mono wafers is ramping much faster this year in wafer productions vs last year. Now to add to that DQ, is suggesting they will reduce cash costs to $6.0/KG. That is close to 20% from the Q4 producton costs, This means that they can easily maintain profitability with handle the price dropping 20% from Q4 levels to $~8/KG . When you recognize they will have 2x the capacity and $6/Kg cost, the spread and margins can be narrower and they can make more money than now come 2020. https://seekingalpha.com/article/4248446-daqo-new-energy-corp-dq-ceo-longgen-zhang-q4-2018-results-earnings-call-transcript?part=single "For example, I can say an example, in Q4, our monosilicon supply is around 61%. So, if you look our gross margin, our monosilicon price ASP is around like $10 and the multi is around $6.30 or whatever. Our ASP is around like renminbi is around like – US dollar maybe around like $9.50. So, we see in Q1, we will get more improved our gross margin, the reason because first of all, the monosilicon percentage will increase to around 77%, 78%,"
  24. 1 point
    I've lost count of how many times they have lied to investors. I buy their audited financial statements but not much more than that. That's just me.
  25. 1 point
    PEGI has been one of my better buys - steady climb and paying great divi
  26. 1 point
    OMG looks like I won on estimize you guys. I was closest on EPS with $1.30. Philip Shen had $0.65 and Colin Rash $0.40.
  27. 1 point
    So they wrote off the inventory last couple Q's and now they sell it and claim revenue with great margins. What a scam. I thought that would be put under other income and not revenues.
  28. 1 point
    I think they have positive earnings of a couple pennies before 1 timers I expect a $1.85 spread on cost to ASP. I am using a lower cost and volume than yours Gross comes in around $12.6M My Opex and Int are slightly higher at $12.2M Q4 though is not relevant. 2019 costs and guidance are. I expect Q1 to be the low for the year in earnings in the low double digits and increasing from there. I expect Q1 costs to be around $7.50 I expect costs to decline slightly from there with production ramps and optimization The second half of 2019 should be stronger as that is were the forecast in volume increases over the first half. This should lead to a slight rise in ASP int he second half even with the new capacity. From this I reasonably expect a full year profit of North of $2 a share. Disclosure: I do not own DQ.
  29. 1 point
    OMG I just noticed that I already had a Q4 estimate back in November. Here's my update. I've just posted in on estimize. OMG I'm the only one forecasting a loss. It's so exciting to be competing against WS names like Philip Shen. Wish me luck you guys! Volume sold: 7200T ASP: $9.8/kg cost: $8.7/kg Gross: $8.3M OPEX&NI: $11.2M EPS: -$0.18 before adjustments P.D. anybody else have an estimate?
  30. 1 point
    Ah, I see, you are narrowly looking at the word Green New Deal and suggesting it is strictly power. Green means many things. Like Getting Chemicals our of building materials. Getting harmful chemicals out of the ground and water. Having healthy natural foods that are not processed or altered (GMO) or hormone injected being fed to to us. Medicines that are consumed and then pissed into the water systems polluting the water. Broaden your scope and this New Deal lays out a template of objectives that are good goals to want to achieve.
  31. 1 point
    Why are you calling First Solar a POS? It seems you have transferred your anger at a certain poster onto the company. The outright hostility some folks here have for FSLR is rather comical. When comparing First Solar and Canadian Solar you really need to go by enterprise value as the debt (and lack of debt) really changes the picture. First Solar has an EV of $3.2B. Canadian Solar is at $2.85B. Redoing forward earnings based on EV leaves FSLR at 13 and CSIQ over 14. Both companies seem to be similarly priced right now. Then consider that First Solar could have gone all SunPower and considered the ramp and startup costs as a Non-GAAP expense. Doing so would have put EPS at around $4. In addition, EPS won't tell the whole picture because in a year or two cash flow will go up dramatically as the new S6 factories start to depreciate. Lastly, FSLR has these earnings based on 17% efficiency panels. Considering that 3 years ago the company created a cell with 22.1% efficiency, it doesn't seem like much of a stretch to think the company can get module efficiency over 20% in the next three years. Doing so would have a dramatic impact on cost per watt and earnings. Solar has gotten to the point where it has gotten cheaper than the operating cost of coal unsubsidized. That means it should really take off soon. Plus, the mad rush to drive prices down should lessen.
  32. 1 point
    JKS' double in 3 months (almost a triple in 4 months) combined with a massive contract with DQ announce the other day (a.k.a. expansion) smells like a secondary is coming.
  33. 1 point
    It's taking off folks! Watch out for 40 before August, now is not the time to take a quick buck.
  34. 1 point
    Your word in God's ear! That would pretty much restore my portfolio to previous highs....
  35. 1 point
    Why do we have to "spin" anything? This is a board for factual discussion.
  36. 1 point
    Chinese city wants 700 MW of new solar within two years: The announcement from the city authorities comes in the wake of the central government’s call for local authorities, electricity companies and big lenders to remove roadblocks to what it designated ‘grid-parity’ PV projects, by which it meant installations which did not benefit from central subsidies but which could be encouraged by local incentives. https://www.pv-magazine.com/2019/02/14/chinese-city-wants-700-mw-of-new-solar-within-two-years/
  37. 1 point
    I'll add that the 13Fs that have been trickling in for FSLR have been very sexy. Some serious purchases last quarter on the weakness.
  38. 1 point
    I expect them to meet or slightly beat, though I haven't looked at the numbers in detail. They are basically sold out for the next two years at fixed prices, so imo that leaves little room for EPS surprises either up or down. Two positives are that prices in the U.S. are holding up well (despite the ominous 2.5GW quota for foreign cells) and that S6 certification is progressing as planned: https://www.pvinfolink.com/post.php?sn=2 https://investor.firstsolar.com/news/press-release-details/2018/First-Solar-Series-6-Completes-CSA-C450-Test-Protocol-at-CSA-Groups-PV-Test-Lab-CFV-Solar/default.aspx Imho FSLR will be quite boring over the next several quarters because they are transparent and predictable. If you prefer a roller coaster with 50% swings then I'd suggest to stick with the CNs.
  39. 1 point
    More on PG&E with commentary on the solar aspect as well as those companies most affected... https://www.forbes.com/sites/greatspeculations/2019/01/27/pge-gets-a-break-and-opportunity-is-still-knocking/#3767dfe56d10
  40. 1 point
    My second recommendation is Sangamo Therapeutics, SGMO. By Feb 7, the company will have a delivery of the results in MPS II and MPS I. They are first in the world to edit the human genome in vivo. MPS II results were released in September where the application reduced negative byproduct GAGs. In Feb expectation is to confirm that IDS enzyme is produced therefore GAGs are reduced by patients' production of IDS, a deficit of the enzyme is a sole root-cause of MPS II disease. The stock volatility may be very high. However, for those with risk acceptance, now and next 7 trading days from today, the stock could move 10 to 15%. If something fails a 20 to 30% may be experienced on Feb 7. There are more stories to this company. If I will see that Feb 7 is validated I will offer a bigger summary. Proceed at your own risk and good luck.
  41. 1 point
    https://www.pv-tech.org/news/canadian-solar-and-signal-bag-contract-for-175mw-new-south-wales-pv-project?fbclid=IwAR3byF0qu_XwNpM_Wj5LK3SE_8J3hQ332YWw7qu5VbYn6QtE9UKQ4THX6WU
  42. 1 point
    FSLR nowhere in sight by the way...
  43. 1 point
    I believe at the time of the spinoff they had only something like 125MW of their 1GW plus in the catalog. The next catalog that came out I believe after the spinoff should have added about 300-400MW more leaving some 800MW not in the catalog. Then of course there is the GW or so a year they were adding after the spinoff that would not be in the catalog. Those post spinoff projects were funded by modules being sold by Jinko with little or no payment down. Those modules are now AR's and notess receivables. Some of the "revenues and profits" from Jinko are from those sales to Jinko New Energy which are at risk of default as well. The CEO is using JKS to float his spinoff. I do not trust Jinko Chairman to have the shareholders interest at heart.
  44. 1 point
    I would be concerned about JKS. They are the guarantor of the debt they spun off with the New Energy spinoff. A very large portion of those projects were not in the catalog and not getting the FIT payments.
  45. 1 point
    GP $620-$700M. Opex $430M+/- Interest $100M+/- ASP $0.27 CPW $0.235(13%GM) on 8GW shipments for revenues The wild card are project sales revenue , power revenues and EPC revenues. Project 130MW Japan @ 3.30 @ 30%GM 700MW @ 1.2/W @ 12.5%GM Power Revenues/Dividend Incomes $40M @ 50%GM EPC $150M @ 15%GM
  46. 1 point
    Low end I see is $1.25 high end range is $2.25. Shipments for revenues in the 8GW range.
  47. 1 point
    Nice to see CSIQ hitting 52-week highs, getting business globally, becoming independent off commodity material swings. I read commentary how they going to fall on their face with their multi products. Not likely if they build solar parks with them as a major user. CSIQ adaptability to business cycles seems superior to any other listed company. And surprisingly the market is recognizing it. Days of $40 per share may not be gone but if anything CSIQ has a chance to reach that in a couple years.
  48. 1 point
    Needham transcript https://seekingalpha.com/article/4233632-canadian-solar-inc-csiq-21st-annual-needham-growth-brokers-conference-transcript?page=1
  49. 1 point
    China unveils an ambitious new push on grid parity solar https://www.pv-magazine.com/2019/01/10/china-unveils-an-ambitious-new-push-on-grid-parity-solar/
  50. 1 point
    A 30% return based on the date of the post and today's closing. The stock is at just above $1.3B market. Two M&A actions, BMY, and CELG mentioned by explo and LLY buying LEXO are putting a bit of fire on the buyout candidates. BMY and Pfizer is a maker of Eliquis and JNJ and Bayer make Xarelto. Andexxa made by Portola is an antidote for the two drugs. Eliquis is more dominant in sales, between overall markets some $12 or $13B in sales in 2019 and more with an available antidote. Now JNJ and Beyer wanted to use Xarelto in the area where Bevyxxa another Portola drug is already approved. Since BMY bought Celgene, JNJ purchase of Portola seems very logical. There is a sense that Portola can help JNJ and the perception that Xarelto has more bleeds with Andexxa. Bottom line Portola is a candidate for a buyout and JNJ seems like a potential buyer. At 4 times of Andexxa $1B sales and perhaps $500M for Bevyxxa when fully running, $6B looks like $96 per share. This will not happen tomorrow, but there is a good potential that stock could be $70 by Q3 of this year. Good Luck.


×
×
  • Create New...